Larger-scale studies are needed to fully establish MPO-ANCA titers as a potential prognostic biomarker in patients with MPO-ANCA ILD, but serological monitoring might be useful in predicting renal involvement in MPO-ANCA ILD patients and of aid in risk stratification. This evidence concerns the gene MPO and interstitial lung disease.